CURRICULUM VITAE

Date Revised: October 20th, 2015Name: Jack T. Rogers, PhDOffice Address: Neurochemistry Laboratory, Division of Psychiatric Neuroscience

Charlestown, MA 02129Tel: 617-726-0475

Home Address: 63 Sunnyside, Arlington, Massachusetts 02474Work Phone: 617-726-8838Work Email: Jack.Rogers@mgh.harvard.eduWork FAX: 617-726-0830Place of Birth: London, EnglandEducation: Dublin, Ireland

Year Degree Field of Study Institution09/73 - 06/77 BA (Hons) Genetics Trinity College Dublin09/77 - 06/79 M.Sc. Genetics University of Pennsylvania09/79 - 06/83 Ph.D. Biochemistry St. Mary’s Hospital, IC, London Robert Williamson, Ph.D.

Postdoctoral Training: Year Title Specialty/Discipline Institution 09/84-08/87 Post doc Applied Biology, Massachusetts institute of Technology

Hamish Munro, MD. 09/87-09/91 Post doc Hematology Brigham and Women’s Hospital, MA

Faculty Academic Appointments:Year Academic Title Department Academic Institution09/92-08/99 Instructor Medicine Harvard Medical School09/99-08/06 Assistant Professor Psychiatry/ Harvard Medical School

Neuroscience08/06 –08/11 Associate Professor Psychiatry/ Harvard Medical School NeuroscienceAppointments at Hospitals/Affiliated Institutions:PastYear Position Title Department Institution08/89-09/93 Assistant biochemist Medicine Brigham and Women’ Hospital08/98-09/00 Associate Biochemist Medicine Brigham and women’s Hospital

CurrentYear Position Title Department Institution

08/00- 08/11 Assistant Scientist Psychiatry Massachusetts General Hospital

Other Professional Positions and Major Visiting Appointments:Year Position/Title Institution08/03-08/06 Visiting Scientist Functional Genomics, Brigham and Women’s Hospital

0809- 09/11 Senior Fellow Mental Health Research Institute, Melbourne, Australia

Major Administrative Leadership Positions:LocalYear Position Title Institution08/03-09/06 Co-Director MGH, Laboratory for Oxidation Biology08/06-08/11 Director Massachusetts General Hospital, Laboratory

for NeurochemistryMember

NationalYear Position Title Institution2002 Chair and Organizer East Coast Iron Meeting

Convenes annually for Iron researchersInternationalYear Position Title Institution2008-Present Coordinator International Prion Discovery Consortium

(Canada and Ireland, Scrapie Therapy)Committee Service:Year Name of Committee Institution/OrganizationLocalMassachusetts General Hospital

1990-2000 Member of the Safety Committee Brigham and Women’s Hospital 2011 Neuroscience Seminar Series Massachusetts General Hospital

(Host to Presenters)

Harvard University

2011 Review Board, Harvard- Harvard University -Undergraduate Research Journal

National

2005-2009 BDCN (F11) Pharmacology National Institutes of HealthStudy Section

2009-2011 Scientific Board American Federation For Aging Research, New York, NY

International

2009-2014 Scientific Board Institute for the Study of Aging, New York, NY

Professional Societies:Year Society Role1985-Present American Association Advancement of Science Member1991-Present American Society for Cell Biology, Member Member2001-Present Society for Neuroscience Member

Grant Review Activities:Year Name of Committee Organization2001 Reviewer, Ad hoc Science Foundation of Ireland2002 Reviewer, Ad hoc Alzheimer’s Association (International) 2003-Present Reviewer, Ad hoc Israeli Science Foundation2010-Present Reviewer, Ad hoc Alzheimer’s Association (UK)2010-Present Reviewer, Ad hoc Hong Kong Science Foundation2011-Present Reviewer, Ad hoc Michael J. Fox Foundation for Parkinson’s Disease

Editorial Activities:Ad hoc ReviewerNatureScienceProceedings of the National Academy of SciencePLoS-ONE Journal of Biological Chemistry Journal of Clinical Investigation Expert Opinions Therapeutic Targets Journal of NeurochemistryJournal of Alzheimer’s DiseaseRNA

Other Editorial RolesYear Role Journal2004-present Editorial Board International Journal of Nanotoxicology

Awards and Honors:Year Name of Award Awarding Organization and Achievement1985 Scholarship Leukemia Research Fund, UK1992 Scholarship EMBO, Translation meeting, Spetses, Greece 2000 Neuroscience Award University of California at San Diego.2004 Conference Fellowship Symposium on Neuroprotection, University of British

Columbia, Vancouver2009 Honorary Senior Fellow Mental Health Research Institute, Melbourne, Australia

2009-2014 Zenith Awardee International Alzheimer’s Associatio

Report of Funded and Unfunded Projects:Funding InformationPastYears Role Funding SourceTitle:Description:1992-1997 PI NIAID R29 $750,000. Title: "Translational control of the acute phase response" (Rogers, JT. PI)The goals of this project were to define mechanism behind our observation that inflammatory cytokines induce translational gene regulatory events during the hepatic acute phase response.

Ferritin mRNA translation was the focus of the project. Until the results of this project were published, cytokines had been thought to regulate genetic expression only by transcription.

1994-1995 PI Alzheimer’s Association $30,000Translational regulation of APP mRNA and Alzheimer's disease.The goals were to study the translational control of the expression of the Alzheimer’s amyloid precursor protein (APP) in astrocytes induced by Interleukin-1. Previously APP gene expression was reported to be regulated at the transcriptional level.

1996-1997 PI American Federation for Aging Research $80,000 Alzheimer's disease and translational regulation of the amyloid precursor protein (APP) Gene. The goals were to define the RNA binding interactions that controlled iron dependent translation of APP mRNA pertinent to the onset of AD.

1997-1999 PI NIA R03 $90,000 Co-regulation of APP and ferritin mRNAs and APP function. The project goal was to define the role of iron regulation of APP and explain our findings that APP is a ferroxidase.

2000-2005 PI Neuroscience Education Research Foundation $75,000 Translational regulation of APP-mRNA.The project goal was to understand the translational control mechanisms for the Alzheimer’s APP (Ab).

2000-2005 PI Message Pharmaceuticals $50,000Therapeutic drug discovery directed to the 5'UTR of the Alzheimer's APP transcript . Our project goal was to define how the APP 5’UTR would offer an RNA target to identify APP translation blockers for AD therapy.

2000-2002: PI ISOA/ AFAR $100,000A new translational regulatory target in the Alzheimer’s APP transcript.The goal of this project was to define the anti-amyloid mechanism by which the anti-cholinesterase phenserine operated therapeutically in Alzheimer’s paradigms.

2002-2005 PI Alzheimer’s Association IIRG $200,000Mechanisms of APP translational control as mediated by its 5'untranslated region.The goals of this project were to identify how inflammatory cytokines influenced APP translation and amyloid burden.

2003-2008 PI N.I.H., R01 $1,000,000RNA therapeutics and Ab precursor protein translation. The goals of this project were to identify al the sequences that control APP expression with a view to therapeutically blocking amyloid production.

2005-2007 PI N.I.H., R03 $85,000Small HTS molecules targeting the APP 5' untranslated region. The goals of this project were to develop and test the anti amyloid efficacy of our high throughput screened APP 5’UTR blockers.

2007-2008 PI N.I.H., R21 $125,000MLPCN screen and characterization of the Parkinson’s disease alpha synuclein 5'UTR blockers. The goals of this grant were to identify the protocol to screen SNCA inhibitors in collaborations with the Broad Institute.

2007-2010 PI ISOA/ADDF $80,000 Development of APP 5'UTR leads for anti-amyloid efficacy in Alzheimer's disease. The goal of this project was to test the tolerance of our high throughput screened ‘APP (translation) blocker-9’ while this agent reduces translation of the amyloid precursor protein ex vivo.

2008-2011 PI N.I.H., R21 $125,000MLPCN screen and characterization of the prion PrP 5’UTR.The goal of this project is to work with the Broad Institute (Cambridge, MA) to screen drugs that block the scrapies infectious agent that cause C.J.D. and mad cow disease.

2010-2014 PI Michael J. Fox Foundation Novel Drug Discovery Program. $150,000Title: Optimization of alpha synuclein based on the drug posiphen for Parkinson’s disease therapy. The goal of this project is to identify analogs of the drug posiphen that can block alpha synuclein translation with a therapeutic role for Parkinson’s disease.

2009-2014 PI Alzheimer’s Association, Zenith Program $500,000Post transcriptional control of APP and iron homeostatic genes in the AD-brain. The goals of this project are to determine how iron-regulatory protein-1 controls APP translation with implications for iron metabolism based on our discovery that APP is a ferroxidase.

PresentYears Role Funding Source Direct Costs

2012-2015 PI NIH R21 $150,000Post Transcriptional Control of hemorrhagic iron damageAims: The goals are to understand the translational control of iron related genes in response to hemorrhagic assault. We will investigate the circumstances by which ferritin and APP safely oxidizes and stores transported brain iron after hemorrhage.

2006-2017 PI Univ. Hong Kong/ NYU funded Neurochemistry Fund $150,000Restoration of visual Nerve cell function from Led (Pb) toxicity.The major goal of this fund is to characterize pathways of restorative neuronal growth via use of translation activators of the iron homeostatic proteins - amyloid precursor protein / ferritin - as Fe transport and storage proteins to combat lead (Pb) associated neurodegenerative disease progression.

2014-2015 PI Neurochemistry Lab Aria Fund Rogers MGH Psychiatry. Characterization of PAMP-2 Aamyloid precursor protein translation inhibitors.The major goal of this internal fund is characterize Aria’s APP 5’UTR translation blockers for Alzheimer’s disease therapeutics.

2014-2015 PI MGH Interim Support for Cognitive Restoration $75,000Translational Control of Manganese driven Neurotoxicity.

This project to study the interaction between manganese and urate for the translation of APP, a-synuclein transcript for Parkinson’s disease therapy to prevent dopaminergic neurodegenerative decline.

Current U with Funding Pending:Years Role Funding Source Direct CostsTitleDescription/Goals/Role

2015-2017 PI NIH R21 $375,000Translational control of Manganese Neurotoxicity.The goals of this project is to test the in vivo iron damage resulting from manganese neurotoxicity through the 5’untranslated region RNA target in the amyloid precursor protein transcript.

2015-2020 PI NIH R01 $1,200,000Translational control of Manganese Neurotoxicity.The goals of this project is to test the in vivo iron damage resulting from manganese neurotoxicity through the 5’untranslated region RNA target sin the amyloid precursor protein transcript and the ferritin transcript. Here, additional to goals to the R21 (above), we will determine how urate improves conditions of manganese toxicity.

2016-2021 PI NIH R01 $1,200,000Translational control of Hemorrhagic iron Damage.The goals of this project are to test how the heme sequestering protein hemopexin signals protective pathways to protect neurons from the in vivo iron damage resulting from neurotoxicity after heme/iron overload after hemorrhage. We will define neuroprotective pathways via the 5’untranslated region RNA target in the amyloid precursor protein and the ferritin transcripts . We will determine how AF102B and yohammine as APP 5’UTR activators improve conditions for neurons overexposed to hemorrhagic iron toxicity.

2015-2020 PI NIH R01 $1,200,000Post-Transcriptional control of Parkinson’s Disease.The goal of this project is to test the link between iron metabolism and Parkinson’s disease pertinent to our discovery of a fully functional iron-responsive element in the a-synuclein transcript. We will define the role that this RNA regulatory domain has to promote PD pathology (alpha-synuclein deposits pertinent to Lewy body formation and gait and enterocytic phenotypes).

Report on Teaching

Formal Teaching of Residents, Clinical Fellows and research Fellows (post-docs):

Prior to start of Harvard appointmentYear Course Title-Role Level of effortStudent type1999-2000 RNA Journal club 40 weeks, 1 hr/wk Fellows studying RNA based control of gene expression at HMS (Co-host, Dr. Marla Berry)

Laboratory and Other Research Supervisory and Training Responsibilities:

Supervised Trainees:

Undergraduate and graduate studentsPastYears Trainee Current position

2000-2001 Nabeil Sarhan, BS (current) West Warwick Rhode IslandUndergraduate thesis Harvard University

2000 Amanda Venti, MD (Current) Physician, Arlington, MAWe published one paper - Venti et al., (2003) Anal NY. Acad. Sci.

2008 Conan Huang, BS (current) Undergraduate Thesis Brown University Undergraduate advisor.

2009-Present Sohan Mikkilineni, Undergraduate, MIT. Sohan published peer reviewed manuscripts in J Neural Transmission (2011) In Parkinson’s disease (2012)

2014 Suthruthi Rajanala Boston University Medical StudentSuthruthi is submitting a peer-reviewed paper to the journal: Neuroscience and Medicine

Junior faculty and Postdoctoral fellows

Years Trainee Current position

1996-2000 Lorene Leiter, Ph.D. Staff Scientist, MIT, Post-doctoral Advisor; co-published twice in the Journal of Biological Chemistry with Dr. Rogers.

2000-Present Xudong Huang, PhD Assistant Professor, Radiology, BWH.Faculty Advisor: Dr. Huang and co-published 20 manuscripts as co-director of the Neurochemistry Laboratory.

2001-2006 Sanghamitra Bandyopadhyay, Ph.D. Assistant Professor, Indian Institute of Toxicology Ongoing collaboration (2014)

Postdoctoral Advisor; co-published 8 peer reviewed papers, including the Journal of Neuroscience research and identification of a patented APP translation blocker in development as a therapeutic agent for Alzheimer’s disease (under pending patent at MGH). Continue to collaborate (2015) and hosted her presentation in the Neuroscience seminar series at MGH (2013).

2004-2012 Catherine Cahill, Ph,D. Instructor, Department of PediatricsMassachusetts General Hospital

2012-2015 Catherine Cahill, Ph.D. Assistant Professor of Pediatrics

Faculty advisor: Catherine co-published 7 manuscripts, including paper of the week and cover issue in Journal Biological Chemistry, receiving a full author profile by the American Society for Biochemistry and Molecular Biology. http://www.jbc.org/content/285/41/e99973/suppl/DC1

2006-2008 Hiromi Gunshin, MD Assistant Professor of Nutrition, U. Mass Amherst (formerly)

Mentor as a visiting MGH Fellow; published 2 manuscripts while at the Neurochemistry Laboratory.

2012-2015 Dr. Yanan Liu , Ph.D. Fellow in the Neurochemistry Laboratory

2013-2015 Dr. Qinjun Li, MD. Fellow and visiting scientistin the Neurochemistry Laboratory.

Thesis Committees

1999 Elyssia Hollams University of Western Australia, Ph.D. Thesis committee2003 Eric Hall Penn State University , Ph.D. Thesis committee2013 Marlies Fischer University College Dublin. Ph.D. Thesis committee

Harvard Medical Student Teaching.2011-214 I am a faculty tutor to the incoming class of Harvard medical students every year. I actively run their annual 6 weeks tutorial groups covering topics related to the molecular biology of causes of human disease (Prof. Randy. King: Course Director).

Local Invited Presentations:Year Title Type of presentationDept/Institution Sponsor

Grand Rounds

2000 Drug Development against the Alzheimer's APP mRNA. Grand RoundsMGH, Department of Psychiatry.

2004 Developments in Alzheimer Neuropharmacology. Grand RoundsMGH, Department of Psychiatry.

2007 Iron and Translational Control of APP and Ferritin. Grand RoundsRNA Therapeutics for Oxidative Stress in Alzheimer’s disease.

Boston University Alzheimer's Disease Research Center.

2012 Iron Homeostasis and Translational Control of the APP Grand Rounds of Alzheimer’s Disease and Down’s Syndrome.Boston University Alzheimer's Disease Research Center.

Seminar (Since 2005)

2005 RNA Based Therapeutics to the Alzheimer's APP Transcript. SeminarInstitute for Neurodegenerative Diseases (MIND).

2005 Iron and APP mRNA Translation: RNA Therapeutics for AD. SeminarGenetics and Aging Research Unit (Dr. Rudolph Tanzi - Host)

2006 Iron and Alzheimer's Disease. SeminarGenetics and Aging Research Unit (Dr. Rudolph Tanzi – Host).

2007 Paroxetine, An SSRI for Depression with Bonus RNA based- Seminar -anti-Amyloid Efficacy for Alzheimer's Disease.

Neuroscience Seminar Series, MGH(East). (Dr. Pradeep Phade – Host).

2008 Linked Translational Control of the APP and Alpha synuclein Seminar and neuroprotection from Oxidative Stress.

MGH Institute for neurodegenerative Diseases.

2009 Alpha Synuclein and APP mRNA Translation: Seminar RNA Therapeutics for Neurodegenerative diseases.

Genetics and Aging Research Unit, MGH.

2012 Iron Homeostasis and Neurodegenerative disease. SeminarGenetics and Aging Research Unit, MGH.

2013 Translational regulation and neurodegenerative disease SeminarMGH Institute for neurodegenerative Diseases. (Oct 2013)

2014 Inhibition of APP and alpha-synuclein improves memory Seminarand learning in a tg mouse model of Alzheimer’s disease and normalizes non-movement symptoms in a tg-mouse model of Parkinson’s disease

MGH Institute for neurodegenerative Diseases. March 05 2014 with Dr. Maria Macccecchini.

2015 Modulation of APP and a-synuclein by manganese Seminarand Iron as model of Parkinson’s disease and Manganism.

Harvard School of Public Health. January 13th 2015 with Dean Wessling-Resnick as the Host.

2015 Chemical Optimization of amyloid precursor Protein translation Seminar blockers.Laboratory for Drug discovery in Neurodegenerative Diseases, Cambridge, MA with Dr. Kevin Hodgetts s the host.

2015 RNA as a therapeutic target for curing neurodegenerative Seminardiseases.

Massachusetts General Hospital. September 2015 with Prof. Lee Gehrke as the host.

2016 Translational regulation as a new line of therapy for neurodegenerative diseases. Seminar

Center for Neurodegenerative Diseases in Dec 2015 with Dr. Dominic Walsh and Dr. Dennis Selkoe as the hosts.

Report of Regional, National and International Invited Teaching and Presentations:RegionalYear Title of presentation or name of course Type of presentation/role (abstract)Location Sponsor/Source of compensation1994-2000 Multiple Presentations, e.g., Invited Speaker, Center for Blood Research (1996), Boston. Mini symposium on Trans-acting factors and Gene Regulation by Cytokines, Center for Blood Research, Annual Seminars2000 The APP mRNA, A New Therapeutic Strategy Speaker

for Alzheimer's Disease. Bio-2000: Conference, Boston, MA. , Bio-2000 conference [Seminar]

2001 Interleukin-1 and Gene Expression Leading Speaker to Alzheimer’s Disease, Speaker

Interleukin Genetics, Woburn, MA, Interleukin Genetics [Seminar]

2002 Work in progress (twice yearly) SpeakerGenetics and Aging Research Unit, MGH

2003 Translational Control of Ferritin mRNA Speaker by Interleukin-1, New RNA Binding Interactions

2005 Drug Discovery for Alzheimer’s disease Speaker Dr. Maurizio Fava, Host The Depression Clinic, Psychiatry, Dept, MGH

2008 Metalobiology of Alzheimer’s Disease SpeakerRadiology, Brigham and Women’s Hospital/ )[Seminar]

2009 Metalobiology of Alzheimer’s Disease SpeakerDr. Rudolph Tanzi (Host):

Genetics and Aging Research Unit

2010 Therapeutic Uses of Ferroxidase Peptides against Stroke SpeakerDr. Xiaoying Wang (Host)

Radiology Stroke Division, MGH

2011 Ferroxidase iron export by APP protects neurons SpeakerDr. Alan Walker, MD (Host)

Pediatrics Division, Massachusetts General Hospital

2012 Ferroxidase iron export by APP protects neurons SpeakerDr. Marianne Wessling-Resnick

Department of Nutrition School of Public Health, Boston, MA

2012 Drug discovery targeted to the PrP 5’UTR: Speaker prion scrapie therapyDr. James Spoonamore (Host)

Broad Institute, Cambridge, MA.

2014 (Nov) Manganese and lead toxicity as drivers of Parkinson’s disease Speaker

Dr. Michael Schwarzschild (Host) Department of Neurology, Massachusetts General Hospital

NationalYear Title of presentation or name of course Type of presentation/role (abstract)Location Sponsor/Source of compensation(Selected 1999-2000)1990 Ferritin Translational Control by Interleukin-1 SpeakerConference on Liver Gene Expression, Cold Spring Harbor Laboratories, New York [Invited Lecture]

1992 Ferritin Translational Control by Interleukin-1 Speaker(Dr. Jonathan Glass, Host)

Dept. of Medicine Louisiana State University

1995 Ferritin mRNA Translational Control Lecturerand the Anemia of Chronic Disease

University wide Seminar series in Clinical Medicine, Rockefeller University

1996 Ferritin mRNA Translational Control SpeakerDr. Kelvin Davies, Host

Albany Medical College. Albany Medical Center [Invited Lecture]

1997 Inflammation and Translational Control Speakerof the Alzheimer's APP holoprotein

Neuroscience Conference, New Orleans, Society for Neuroscience [Invited]

1998 Inflammation and Alzheimer's Disease SpeakerFASEB meeting (Neuronal damage and Repair) in Portland Oregon [Invited Lecture]

2001 Anti-Cholinerserase Therapeutics to the Alzheimer's Amyloid Precursor Protein Transcript. Speaker

Institute for the Study of Aging, Tarrytown, NY, ISOA [Invited Lecture]

2002 Drug Discovery Targeted to the Alzheimer's Speaker APP 5’Untranslated regionInstitute for the Study of Aging, Tarrytown, NY., ISOA [Invited Lecture]

2003 Iron and the Alzheimer's Amyloid Precursor Protein SpeakerDr. Thomas Maciag, Host

Maine Medical Center [Neuroscience Seminar series]

2003 Iron and Alzheimer's Disease SpeakerDr. Jonathan Smith, Host

Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio [Cell Biology Seminar series]

2003 Alzheimer’s Disease, Metals Speakerand the APP-mRNA 5’ untranslated region

ACS Symposium, Jarvits Center, New York, NY, American Chemical Society Symposium

2003 Paroxetine and N-acetycysteine Targeted to the Alzheimer's Speaker APP 5’Untranslated regionInstitute for the Study of Aging, Teaneck, New Jersey [Invited Lecture]2004 Iron and Drug Discovery as a therapy for Alzheimer's Disease. Speaker

Dr. Jane Welch, HostDepartment of Biosciences, Texas A&M University [Seminar series in Cell Biology]

2005 Drug Screening against the Alzheimer's APP mRNA Transcript: SpeakerRNA based Disease Therapeutics

Buck Institute, San Francisco, Buck Institute for Aging Research [Seminar series in Pharmacology]

2005 Iron and the Function of the Amyloid Precursor Protein SpeakerDr. Danillo Tagle, Host

National Institute for Neurodegenerative Diseases [Conference on Brain Disorders with iron Accumulation, NIH, Bethesda, Maryland, Invited Lecture]

2005 New wave of RNA Therapeutics for Alzheimer’s Disease SpeakerInvited Speaker of the Fellows at the National Institute of Aging (Intramural Research, Baltimore, MD

2005 In Vivo efficacy of FDA drugs for Alzheimer's Disease SpeakerISOA Conference, Rockefeller University, NY, NY

2006 Role of Iron and Copper in the Function and Regulation Speakerfor the Alzheimer's Amyloid Precursor Protein

National Institute for Neurodegenerative Diseases [Invited Lecture in Wilson’s Disease Workshop, Bethesda, Maryland].

2007 Iron and Abeta Amyloid Precursor Protein and Ferritin Translation: SpeakerRibotargets for Alzheimer’s disease Therapy

Hershey Medical Center, PA [Invited Lecture in the series in Cell Biology]

2008 Iron Uptake and Ferritin and APP Translation: SpeakerRibotargets for Cancer Therapy

LSU Cancer Center, Shreveport, LA [Invited Lecture in the series in Cancer Biology]

2009 Alzheimer's Drug Discovery Targeted to the Non-amyloidogenic path Speakerof APP mRNA Translation linked to alpha-secretase (ADAM-17) expression

The 237th ACS National meeting, Salt Lake City, Utah (March 22), Novel Targets for the treatment of Alzheimer’s disease

2009 Elevated Serum Ferritin Level Correlate with Faster SpeakerDisease Course in Amyotrophic Lateral Sclerosis,

61st National meeting of the American Academy of Neurology [Invited Talk on the program in Clinical and Translational Research, Seattle, Washington]

2010 Iron Homeostasis & Translation and Neurodegenerative diseases SpeakerDr. Huntington Potter (Host)

Johnny Bird Center for Alzheimer’s Disease, University of South Florida2011 Iron Homeostasis and Translation Control of the key Neurodegenerative Speaker

Amyloid Precursor Protein of Alzheimer’s Disease Dr. Bruce Lamb, (Host) Cleveland Clinic Lerner Institute [Invited Lecture in the Neuroscience Seminar Series]

2011 Targeting Alzheimer’s and other Neurodegenerative Diseases Speakervia a Novel Mechanism of Action: Maria Maccechini, Nigel Greig, Virginia Lee (Host)

University of Pennsylvania.

2013 Translational control during Neurodegenerative disease processes. SpeakerDr. George Perry, (Host)University of Texas at San Antonio [Invited Lecture in the Neuroscience Seminar Series]

2013 RNA Regulatory Events in Neurodegenerative Iron Metabolism.Dr. Martin Sadowski, (Host) Speaker

The Comprehensive Center on Brain Aging and Silberstein Alzheimer's Institute, NYU Medical Center

2014 A Novel 5’ Untranslated Region Translation Co-Blocker of the Amyloid Precursor Protein and Prion (PrP); Interface Therapy of Spongioform Encephalopathies and Alzheimer’s disease.

Drug Discovery and Therapy World Congress 2014, June 16-19th, Boston, MA. Speaker.

International

Year Title or course name Type of presentation/role (abstract)Location Sponsor/Source of compensation

1993 Cytoplasm’s role in the Post-Transcriptional LecturerRegulation of Gene Expression

Conference Jacques Monod, Toulon, France, INSERM [Invited Lecture]

1999 Ferritin and APP Translation: from Anemia to Alzheimer's Disease LectureProfessor Prem Ponka (Host)

McGill University, Montreal, Lady Davis Institute, McGill University, Montreal, CA [Invited Lecture]

2003 M-1 Mucarinc Acid Agonists Speakerand Anticholinesterase Drugs for Alzheimer's Disease

AD/PD meeting in Seville, Spain (May 2003).[Invited Lecture]

2004 Protective Strategies for Neurodegenerative Diseases SpeakerSeventh International Conference on Neuroprotection,

Vancouver Canada, NIH [Invited Lecture]

2004 RNA Targeting as a Therapeutic Strategy Speakerfor Neurodegenerative Diseases,

UCD, Dublin, Ireland [Invited Lecture in Cell Biology Seminar series]

2005 Therapeutic Targeting Neurodegenerative disease genes Lecturer Prof. J-M. Moulis, Host

Seventh Winter Research Conference on Free Radicals, Les Houches, CNRS, France [Invited Lecture]

2007 Neuroscience of RNA Regulatory Events in Alzheimer's Disease PresenterProf. Brian Harvey, Host

Royal College of Surgeons, Dublin, Ireland [Invited Lecture]

2008 Iron and Translation of the Amyloid Precursor Protein and Ferritin; SpeakerRiboregulation against neural oxidative damage in Alzheimer's Disease

Biochemical Society Focused Meeting on Metals and Neurodegenerative Diseases [Invited Lecture, London, England]

2009 APP Translation Inhibition as a Novel Therapeutic Strategy Speaker for Alzheimer’s disease.

Oral Presentation International Conference on Alzheimer’s Disease. [Invited Oral presentation, Vienna Austria].

2010 APP Translational Control: the Ferritin Paradigm. SpeakerSeminar on iron and neural pathways at University College DublinDublin Ireland [Invited Lecture, Professor Mark Rogers, Host]

2010 Alpha synuclein Translational control: the Ferritin Paradigm. SpeakerOral presentation at the meeting on Iron and Neurodegeneration in the Brain.Technion University,Haifa, Israel, [Invited Lecture, Professor Moussa Youdim, Host].

2011 Iron Regulatory Proteins and Neurodegenerative disease. Session Leader Oral presentation at the East Coast Iron Meeting, University of Toronto.Toronto Canada, [Invited Session Chair, Dr. James F. Collins, Host].

2012 RNA regulatory events in neurodegenerative iron metabolism. Session LeaderPlenary speaker at the Taishan Academic Forum: Brain Function and Disorders.Qingdao UniversityQingdao, China, [Invited session Chair, Dr. Jiang Hong, Host].

2014 Manganese toxic responses and APP TranslationOral Presentation to the hematology Department, University of Goettingen,Goettingen, Germany [Invited Lecture, Dr. Vivek Venkataramani].

2015 Manganese toxic responses and APP TranslationInvited Oral Presentation at the meeting on metal toxicity in brain disorders London England

Report of Technological and Other Scientific Innovations:High throughput screening or therapies for Neurodegenerative disease

I was in the team to develop the software toolset for high throughput screening protocol of the APP 5’UTR at the Columbia genome center.

The leads are published as part of public service in NCBI (PUBCHEM) as public-access probes of significance to inhibit the translation of APP (Alzheimer’s disease), prion (scrapie) and alpha-synuclein (Parkinson’s disease).

I joined to the high throughput screening initiative of the NIH after which we collaborated extensively with the Columbia University Genome center (James Rothman, Director). We screened and identified APP and a-synuclein inhibitors from which a key patent is pending.The Neurochemistry Laboratory at MGH collaborated with Broad Institute to high throughput screen the alpha-synuclein and prion scrapie 5’untranslated regions in an effort to accelerate pharmacological intervention for Parkinson’s disease and scrapie spongioformopathies. Alpha synuclein translation blockers are currently being tested as a component of a pending patent with the Melbourne research center, Australia. The prion screen is being completed and we are projected to collaborate with Dr. David Westaway (University of Edmonton). As part of this consortium, we also collaborate with Prof. Mark Rogers, University College Dublin). In this process we will develop prion PrP 5’UTR translation blockers for drugs that prevent the spread of scrapie in sheep and humans.

Probe Reports already contributed to PUBCHEM are as follows:-

1. Ross NT, Metkar S, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers JT, Schreiber SL. ONLINE Probe Report of the Molecular Libraries Network of the NIH, pathway to discovery. Title: Identification of a small molecule that selectively activates alpha-synuclein translational expression.

2. Ross NT, Metkar SR, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers JT, Schreiber SL. ONLINE Probe Report of the Molecular Libraries Network of the NIH, pathway to discovery. Title: Identification of a small molecule that selectively inhibits alpha-synuclein translational expression.

PatentsUS Patent no. 6,310,197 Translation enhancer element of the human amyloid precursor protein gene.US Patent no. 7.034,000 Ferroxidase peptides from the human amyloid precursor protein.Int. patent oublished and pending: APP Translation blockers based on the benzimidazole backbone.

Report of Education and Service to the Community:Year Role Organization or institution2000 Invited speaker Maine Teachers Association, Portland Maine2009 Invited speaker Whitehead Institute, New Horizons on Drug Discovery 2009 Panelist Alzheimer’s Association Disorders and Diseases Panel.

2011-2014 Invited Presenter Co Presentation with Dr. James Spoonamore at the Broad Inst.Cambridge, MA

Report of Scholarship:PublicationsPeer-Reviewed Publications in print or other media

Research investigations1. Rogers JT, Kalsheker N, Wallis S, Speer A, Coutelle C, Woods D, Humphries, S.E. The isolation of

human alpha1-antitrypsin inhibitor cDNA clones. Biochem Biophys Res Communications 1983 116:375-378.

2. Myklebost O, Williamson R, Markham AF, Myklebost SR, Rogers JT, Woods D, Humphries SE. The isolation and characterization of cDNA clones for human apoliprotein CII. J Biol Chem 1984 259:4401-4404.

3. Coutelle C, Speer A, Rogers JT, Humphries S, Williamson R. Construction and partial characterization of a human liver cDNA library. Biomed Biochim Acta 1985 44:421-431.

4. Rogers J, Munro HN. Translation of ferritin light and heavy subunits mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells. Proc Natl Acad Sci USA 1987 84:2277-2281.

5. Rogers JT, Bridges KR, Durmowicz GP, Glass J, Auron PE, Munro HN. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990 265(24):14572-14578.

6. Steel DM, Rogers JT, DeBeer MC, DeBeer FC, Whitehead AS. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: the roles of mRNA accumulation, poly(A) tail shortening and translational efficiency. Biochem J 1993 291 (Pt 3):701-707.

7. Rogers J, Lacroix, L., Durmowicz, G., Kasshau, K., Andriotakis J., Bridges, KR. Role of cytokines in the regulation of ferritin gene expression. Adv Exp Med Biology. 1994 356:127-132.

8. Rogers JT, Andriotakis JL, Lacroix L, Durmowicz GP, Kasschau KD, Bridges KR. Translational enhancement of H-ferritin mRNA by interleukin-1 beta acts through 5' leader sequences distinct from the iron responsive element. Nucleic Acids Res 1994 22(13): 2678-2686.

9. Toth I, Rogers JT, McPhee JA, Elliott SM, Abramson SL, Bridges KR. Ascorbic acid enhances iron-induced ferritin translation in human leukemia and hepatoma cells. J. Biol. Chem. 1995 270(6):2846-2852.

10. Rogers JT. Ferritin translation by interleukin-1and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996 87(6): 2525-2537.

11. Leedman PJ, Stein AR, Chin WW, Rogers JT. Thyroid hormone modulates the interaction between iron regulatory proteins and the ferritin mRNA iron-responsive element. J Biol Chem 1996 271(20):12017-12023.

12. Nilsson L., Rogers JT, Potter H. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. Frontiers in Bioscience 1998 3:436-446.

13. Toth I, Yuan L, Rogers JT, Boyce H, Bridges KR. Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. J Biol Chem 1999 274(7): 4467-4473.

14. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences J. Biol. Chem. 1999 274(10): 6421-6431.

15. Cahill CM, Rogers JT. Anti-idiotypic sera against monoclonal anti-porcine growth hormone antibodies: production in rabbits and characterization of specificity. J. Immunoassay. 1999 20(1-2): 45-55.

16. Thomson AM, Rogers JT, Leedman PJ. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int. J. Biochem. Cell. Biol. 1999 31(10): 1139-1152.

17. Thomson AM, Rogers JT, Walker CE, Staton JM, Leedman PJ. Optimized RNA gel-shift and UV cross-linking assays for characterization of cytoplasmic RNA-protein interactions. Biotechniques. 1999 27(5): 1032-1042.

18. Thomson AM, Rogers JT, Leedman PJ. Thyrotropin-releasing hormone and epidermal growth factor regulate iron-regulatory protein binding in pituitary cells via protein kinase C-dependent and -independent signaling pathways. J Biol Chem. 2000 275(41): 31609-31615.

19. Shaw KTT, Utsuki T, Rogers JT, Yu, Q-S, Grieg NH. Translational regulation of Alzheimer's beta-amyloid Precursor Protein mRNA by a putative interleukin-1 responsive element, a new target for drug development. Proc Natl Acad Sci USA 2001 98:7605-7610.

20. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, Kishi F, Hentze MW, Rouault TA, Andrews NC, Hediger MA. Iron-dependent regulation of the divalent metal ion transporter. FEBS Letts 2001 509(2): 309-316.

21. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002; 277(47): 45518-28.

22. Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, Gullans SR. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci 2002 19(1-2): 77-82.

23. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci. 2003 20(3):267-75.

24. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, Rogers JT. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimer’s Dis. 2003 5(2):81-90.

25. Morse LJ, Payton S, Cuny G, Rogers JT. FDA Pre-Approved Drugs Targeted to the Translational Regulation and Processing of the Amyloid Precursor Protein. J Mol Neurosci 2004 24:129-136.

26. Venti A, Giordano T, Eder P, Bush A, Lahiri DK, Greig N, Rogers JT. Integrated role of desferrioxamine and phenserine targeted to the Iron-responsive Element in the 5'UTR of the APP transcript. Ann NY Acad Sci 2004 1035:34-48.

27. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Current Drug Targets. 2004 5: 535-551.

28. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004 39 (11-12)1641-1649.

29. Greig NH, Giordano T, Zhu X, Yu Q, Perry TA, Holloway, HW, Brossi A, Rogers JT, Samamuri K, Lahiri DK. Thalidomide-based TNF-alpha Inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis. 2004 64:1-9.

30. Thomson AM, Cahill CM, Kassachau KD, Toth I, Epis MR, Bridges KR, Leedman PJ, Rogers JT. The acute box cis-element in human H-ferritin mRNA 5'-untranslated region is a unique translation enhancer that binds poly(C)-binding proteins. J Biol Chem 2005 280:30032-30045.

31. Tucker S, Ahl M, Bush A, Westaway D Huang X, Rogers JT. Pilot in-vivo studies of the APP 5’UTR directed FDA pre-approved drugs, paroxetine, erythromycin and N-acetyl-cysteine to reduce amyloid burden in an animal model for Alzheimer’s Disease. Current Alzheimer’s Research 2005 2:249-254.

32. Bandyopadhyay S, Huang X, Cho H, Greig NH, Youdim MB, Rogers JT. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transm Suppl. 2006;(71):237-247.

33. Tucker S, Ahl M, Cho H-H, Bandyopadhyay S, Cuny G, Bush A, Goldstein L, Westaway D, Huang X, Rogers JT. Therapeutics of FDA drugs directed to the amyloid precursor protein mRNA non coding regions, in vivo efficacy. Current Alzheimer's Research 2006 3 (3):221-227.

34. Bandyopadhyay S, Ni J, Ruggiero A, Walshe K, Rogers MS, Chattopadhyay N, Glicksman M Rogers JT. A High-throughput drug screen targeted to the 5’untranslated region of Alzheimer’s amyloid precursor protein mRNA. J. Bio Mol Screen 2006 11 (5): 470-480.

35. Bandyopadhyay S, Hartley D, Cahill CM, Lahiri D, Chattopadhyay N, Rogers JT. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 & ADAM-17) cleavage of APP in human astrocytic cells that requires p38 MAP kinase. J Neurosci Res 2006 84(1):06-18.

36. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 2007 14(27): 2848-2864.

37. Friedlich AL, Tanzi RE, Rogers JT. The 5'-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol Psychiatry 2007 12(3):222-223.

38. Chen J, Zhu J, Cho H-H, Cui K, Li F, Zhou X, Rogers JT, Huang X, Wong STC. Differential cytotoxicity of metal oxide nanoparticles. J. Exp. Nanosci. 2008 2:321-328.

39. Kong W, Vanderberg CR, Gunshin H, Rogers JT, Huang X. Independent component analysis application to microarray gene expression data. Biotechniques 2008 45(5):501-520.

40. Qureshi M, Brown JR, Brown RH, Rogers JT, Cudkowicz ME. Serum ferritin and metals as risk factors for amyotrophic lateral sclerosis. Neurology J 2008 2:51-54.

41. Cahill CM, Rogers JT. Interleukin-1b induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase dependent AKT/IkB kinase alpha pathway targeting activator protein-1. J Biol Chem 2008 283:25900–25912.

42. Patel N, Hoang D, Miller N, Ansaloni S, Rogers JT, Huang Q, Lee JC, Saunders AJ. Micro RNAs can regulate human APP levels. Mol Neurodegeneration 2008 3(1):10-18.

43. Kong W, Mou X, Liu Q, Chen Z, Vanderburg CR, Rogers JT, Huang X. Independent component analysis of Alzheimer’s disease DNA gene expression data. Mol Neurodegeneration 2009 4(1):5-20.

44. Olivares D, Huang X, Branden L, Greig NH and Rogers JT. Physiological and pathological Role of alpha synuclein in Parkinson’s disease through iron mediated oxidative stress; The role of a putative Iron-responsive Element. Int. J Mol. Sci. 2009 10:1226-1260.

45. Maloney B, Ge YW, Petersen RC, Hardy J, Rogers JT, Pérez-Tur J, Lahiri, DK. Functional Characterization of three single nucleotide polymorphism present in the human apo-E promoter: differential effects in neuronal cells and on DNA protein interactions. Am J Med Genet 2009, 999:1-17.

46. Pang CY, Hu BQ, Shi Y, Vanderburgh CR, Rogers JT, and Huang X. Special local clustering algorithm for identifying the genes associated with Alzheimer’s disease. IEEE Transactions in Nanobioscience. 2010 9:1536-1241.

47. Greig NH, Becker RE, Yu Q, Holloway HW, Tweedie D, Ingram ML, Maccecchini ML, Rogers JT, Sambamurti K, Lahiri DK. From natural products to Alzheimer experimental therapeutics: eserine based drugs as symptomatic and disease altering agents. 2010. Progress in Nutrition. 12(1) 58-63.

48. Duce J, Tsatsanis A, Cater MA, James S, Robb E, Cho HH, Galatis D, Moir R, Masters C, McLean C, Tanzi RE, Cappai R, Barnham K, Ciccotosto GD, Rogers JT, Bush AI. (Co Senior/ Corresponding Authors). Iron-export ferroxidase activity of b-amyloid precursor protein is inhibited by Zinc in Alzheimer’s disease. Cell 2010 142:857-67.

49. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT. Selective translational control of the Alzheimer’s amyloid precursor protein transcript by Iron-regulatory Protein-1. J. Biol. Chem 2010 285: 31217-32. (Cover issue and Paper-of-the-Week) Neurochemistry Laboratory was profiled in the American society for Molecular Biology.

50. Ross NT, Metkar S, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers JT, Schreiber SL. ONLINE Probe Report of the Molecular Libraries Network of the NIH, pathway to discovery. Title: Identification of a small molecule that selectively activates alpha-synuclein translational expression.

51. Ross NT, Metkar SR, Le H, Burbank J, Cahill C, Germain A, MacPherson L, Bittker J, Palmer M, Rogers JT, Schreiber SL. ONLINE Probe Report of the Molecular Libraries Network of the NIH, pathway to discovery. Title: Identification of a small molecule that selectively inhibits alpha-synuclein translational expression.

52. Rogers JT, Mikkilineni S, Cantuti Castelvetri I, Smith D, Bandyopadhyay S, Cahill CM, Maccecchini ML, Lahiri DK, Greig NH (2010). The alpha-synuclein 5’untranslated region 50 translation blockers: anti-alpha synuclein efficacy of cardiac glycosides. J Neural Transm. 2011 118; 493–507.

53. Duce, JA., Ayton,S., Miller, AA., Tsatsanis, A., Lam, LQ., Leone, L., Corbin, JE., Butzkueven, H, Kilpatrick, TJ., Rogers, JT., Barnham, K., Finkelstein, D., Bush, AI (2012). Amine oxidase activity of beta-amyloid precursor protein modulates systemic and local catecholamine levels. Molecular Psychiatry. 2012, 1–10.

54. Mikkilineni, S, Cantuti Castelvetri, I., Cahill, CM., Greig, N, Rogers, JT. The anticholinesterase phenserine and its enantiomer posiphen as 5’untranslated region directed translation blockers of the Parkinson’s alpha synuclein expression. Parkinson’s disease 2012: 142372.Epub 2012.

55. Hu B, Jiang G, Pang C, Wang S, Liu Q, Chen Z, Vanderburg CR, Rogers JT, Deng Y, Huang X. Assessment of gene order computing methods for Alzheimer’s disease. BMC Med Genomics. 2013;6 Suppl 1:S8. doi: 10.1186/1755-8794-6-S1-S8. 2013, PMID: 23369541 Free PMC Article.

56. Lahiri DK, Maloney B, Rogers JT, Ge YW. PuF an anti metastatic and developmental signaling protein interacts with the Alzheimer’s amyloid precursor protein via a tissue specific proximal regulatory element. BMC Genomics. 2013;14:68. doi: 10.1186/1471-2164-14-68. PMID: 23368879 [PubMed - in process] Free Article.

57. Yu QS, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, Ray B, Lahiri DK, Rogers JT, Greig NH. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-synuclein synthesis, interleukin-1β release, and cholinergic action. Antiinflamm Anti-allergy Agents Med Chem. 2013 Jan 22. PMID: 23360256.

58. Hahl P, Davis T, Washburn C, Rogers JT, Smith A. Mechanisms of neuroprotection by hemopexin: modeling the control of heme and iron homeostasis in brain neurons in inflammatory states. J Neurochem. 2013 Jan 25. doi: 10.1111/jnc.12165. PMID: 23350672 [PubMed].

59. Bandyopadhyay, S., Cahill, C., Balleidier, A, Huang, C., Lahiri, DK., Huang, X., Rogers, JT. Novel 5’Untranslated Region Directed Blockers of Amyloid Precursor Protein Translation: Implications for Alzheimer’s disease and Down syndrome. PLoS-ONE (2013). Volume 8 | Issue 7 | e65978.

60. Yunlong Tao, Yu Wang, Jack T. Rogers and Fudi Wang. Perturbed Iron distribution in Alzheimer’s disease serum, cerebrospinal fluid and selected brain regions: a systematic meta-analysis. Journal of Alzheimer’s Disease (2014) J. Alzheimer’s Disease 2014;42(2):679-90.Perturbed Iron Distribution in Alzheimer's Disease Serum, Cerebrospinal Fluid, and Selected Brain Regions: A Systematic Meta-Analysis..

61. Scott Ayton, Peng Lei, Dominic Hare, James Duce, Jessica George, Paul Adlard, Catriona McLean, Jack T. Rogers, Robert Cherny, David Finkelstein, and Ashley I Bush. Parkinson's disease iron deposition caused by nitric oxide-induced loss of APP. Journal of Neuroscience. 2015. February 25, 2015 • Volume 35 Number 8. 3591.

62. Catherine M. Cahill, Weishu Zhu, Elias Oxiolor Yao-Jong Yang, Bosco Tam, Markus Lee, Susruthi Rajanala, Yanyan Liu, Chienwen Su, Haining Shi, Bryan Hurley, Jack T Rogers, W Allan Walker (co-senior)/ PLoS-ONE (2015), Accepted and in Press. The Activator-Protein-1 transcription factor regulates Interleukin-6 gene transcription in response to IL-1b in the developing enterocyte.

63. Jack T. Rogers, Vivek Venkataramani, Cecilia Washburn, Yanyan Liu, Vinusha Tummala, Hong Jiang, Ann Smith, Catherine M. Cahill. Journal of Neurochemistry. Accepted and Undergoing Minor revisions 2015/2016. Model of Lead (Pb) Neurotoxicity: Translational Control of the APP Protects Pb Exposed Neurons from Labile Iron Toxicity.

Reviews/Chapters/Editorials (peer reviewed only)

1. Munro HN, Leibold EA, Vass JK, Aziz N, Rogers JT, Murray M, White K. Ferritin gene structure and expression. In: Spik G, Montreuil J, Crighton RR, Mazurier J, editors. Proteins of Iron Storage and Transport. Proceedings of the VIIth International Conference on Proteins of Iron, Amsterdam: Elsevier. 1985 p. 331-341.

2. Munro HN, Aziz N, Leibold E, Murray M, Rogers JT, Vass K, White K. The ferritin genes: Structure, Expression, and Regulation. Ann N Y Acad Sci 1988 526:113-123.

3. Munro HN, Leibold EA, Aziz N, Murray MT, White K, Rogers JT. Ferritin Gene Structure and Expression. Ponka P, Schulman HM, Woodworth R, editors, Iron transport and storage, CRC Press, Boca Raton. In: Ponka P, Schulman HM, Woodworth, P, 1990 pp 133-48.

4. Rogers JT. Genetic regulation of the iron transport and storage genes: Links with the acute phase response. Lauffer R editor, Iron and Human Diseases. CRC Press, Boca Raton, 1992 77-104.

5. Bush AI, Atwood CS, Goldstein LE, Huang X, Rogers JT. Could Ab and APP be antioxidants? J. Alzheimer's Disease 2000 2:1-7.

6. Lahiri DK, Utsuki T, Shaw K, Ge YW, Sambamurti K, Eder PS, Rogers JT, Farlow JT, Giordano, T, Greig NH. Phenserine regulates translation of the b-amyloid precursor protein message. 2001 In: Mapping the Progress of Alzheimer's and Parkinson's disease, Yoshikuni Mizuno, Abraham Fisher, Israel Hanin (Eds). 211-215.

7. Rogers JT. Targeting an RNA structure in the Alzheimer's amyloid precursor protein gene as a new therapeutic strategy for Alzheimer's disease. H Fillit and Alan O’Connell, Eds. 2001:74-88.

8. Rogers JT., Huang X., Bush AI. Therapeutic targets for Alzheimer's disease. In: Neuroprotection, Eng Lo and Joseph Martwah, Eds. Arizona: Prominent Press; 2002. Pp561-603.

9. Friedlich A, Huang X, Nagano S, Rogers JT, Goldstein L, Bush, AI, Multhaup G, Beyreuther K, Stremmel W, Bayer T. Importance of copper and zinc in Alzheimer’s disease and the biology of the beta amyloid protein and amyloid precursor protein. In: Metal Ions and Neurodegenerative Disease. P Zatta, ed., Singapore: World Sci; 2003, pp 245-262.

10. Lahiri DK, Chen D, Lahiri P, Rogers JT, Greig NH, Bondy S. Melatonin, Metals And Gene Expression: Implications In Aging And Neurodegenerative Disorders. Ann NY Acad Sci. 2004; 1035:216-230.

11. Greig NH. Mattson MP, Perry TA, Chan S, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases. Ann NY Acad Sci 2004 1035:290-315.

12. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for development of cholinesterase Inhibitors as anti Alzheimer's agents. Current Pharmaceutical Design. 2004 10(25):3111-3119.

13. Huang X, Moir RD, Tanzi RD, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. NY. Acad. Sci. 2004 1012:153-163.

14. Rogers JT, Greig NH, Lahiri DK, Fisher A. Translation and processing of the amyloid precursor protein in response to an M1-muscaric agonist and an acetyl cholinesterase inhibitor. In: Therapeutic Strategies in Neurodegenerative Diseases. Fisher, A and Hanin, I, eds. NY: Paul Dunitz 2005. p. 265-278.

15. Rogers, JT. APP and ferritin translation, metals and Alzheimer's disease. Sessler JL, editor. Medicinal Inorganic Chemistry (Am. Chem. Soc. Symposium series), 2005 215-251.

16. Liu G, Huang W, Moir R, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, Huang X. Metal Exposure and AD Pathogenesis. Journal of Structural Biology 2006; 155 (1):45-51.

17. Lahiri DK, Ge Y-W, Rogers JT, Sambamurti K, Greig N, Maloney. Taking down the Unindicted co-conspirators of the Ab peptide mediated cell death, shared regulation of BACE and APP genes Interacting with CREB. Current Alzheimer Research 2006 3(5):475-83.

18. Patel AK, Rogers JT, Huang X. Flavanols, mild cognitive impairment, and Alzheimer’s dementia. Int. J. Clin. Exp Med. 2008:181-191.

19. Yi J, Horky LL, Friedlich AL, Shi Y, Rogers JT, Huang X. L-arinine and Alzheimer’s disease. Int Clin Exp Pathol. 2009 2(3):211-38.

20. Rogers JT, Bush AI, Cho H-H, Smith D, Thomson AM, Friedlich A, Lahiri DK, Leedman PJ, Huang X, Cahill CM. Iron and the translation of APP and ferritin; riboregulation against neural oxidative damage in AD. Biochem. Soc. Trans. 2008 36:1282-1287.

21. Zhao W, Liu Y, Cahill CM, Yang W, Rogers JT, Huang X. The role of T Cells in osteoporosis: an update. Int. J. Clin. Exp Pathol. 2009 20; 2(6): 544-552.

22. Cahill CM, Lahiri DK, Huang X, Rogers JT. APP & SNCA translation: Implications for Iron and Inflammation on Neurodegenerative Diseases Biochim Biophys Acta 2009 1790:615-628.

23. Lahiri DH, Ghosh, Rogers JT, Bondy S and Greig NH. Role of nitric oxide in neurodegeneration and vulnerability of neuronal cells to nitric oxide metabolites and reactive oxygen species. In Aging and Age-Related Disorders, 2010. Eds, Bondy, S. C. and Maiese, K, Humana Press, Totowa NJ, 2010.

24. Bandyopadhyay S, Huang X, Lahiri DH, Rogers JT. Drug discovery targeting metallobiology of Alzheimer’s Disease. Expert. Opin. Ther. Targets 2010 14(11): 1177-1197.

25. Olivares, D, Deshpande, VS, Shy, Y, Lahiri, DK., Greig, NH., Rogers, JT., Huang,X. N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer's Disease, Vascular Dementia and Parkinson's Disease. Curr. Alzheimer Res 2012, 9, 000-000.

26. Cahill, CM., Rogers, JT., Walker, A. The role of phosphoinositide-3-kinase signaling intestinal Inflammation. J. Signal Transduction 2012: 358476. Epub 2012.

27. Bandyopadhyay, Rogers, JT. Alzheimer's Disease Therapeutics Targeted to the Control of Amyloid Precursor Protein Translation: Maintenance of Brain Iron Homeostasis. Biochemical Pharmacology. 2014 Feb 7. pii: S0006-2952(14)00071-9.

28. Monica A. Lu, Susruthi Rajanala, Sohan V. Mikkilineni, Catherine M. Cahill, Robert Brown, James D. Berry, Jack T. Rogers. Neuroscience and Medicine. Original Bioinformatics paper. Accepted and In Press 2015/2016. The 5’-Untranslated Regions of the C9orf72 mRNA Exhibits a Phylogenetic Alignment to the Cis-aconitase Iron--responsive Element; Novel Therapies for Amytrophic Lateral Sclerosis.

Abstracts (Last Three years)

1. Friedlich A, Cho HH, Tanzi RE, Moir R, Bush AI, Huang X, Rogers JT. An Iron--responsive Element in the alpha synuclein transcript. Myselle Harvard-wide Psychiatry Research Symposium. 2008 (Poster Awarded First Prize).

2. Duce J, Rogers JT, Tsatsanis A, Moir R, Robb E, Leong SL, Harding SM, Venti A, Masters C, Cappai R, Tanzi RE, Bush AI. Alzheimer's disease -amyloid protein precursor is ferroxidase II, a ceruloplasmin-like iron detoxification Enzyme. Alzheimer’s Association Meeting, Washington DC. 2008.

3. Rogers JT, Cahill CM, Cho, HY, Moncaster J, Goldstein LE, Xie Z, Huang X. Alzheimer's disease drug discovery targeted to the non-amyloidogenic path of APP mRNA translation linked to alpha-secretase (ADAM-17) expression. Meeting ACS, April 2009 (invited Oral Presentation).

4. Qureshi ME, Cudkowicz DA, Schoenfeld Y, Paliwal K, Nelson, Rogers JT, Brown Jr, RH Elevated serum ferritin levels correlate with faster disease course in ALS. American Academy of Neurology, Seattle Washington. 2009 (J Rogers, Oral presentation).

5. Rogers JT, Huang X, Goldstein LE, Moncaster JA, Lahiri DK, Cahill CM, Cho HH, Fischer M, Glicksman M, Cuny G, Rogers MS, Greig NH, Smith DH, Branden L. Specific APP translation blockers as a therapeutic intervention for Alzheimer’s disease. Alzheimer’s and Dementia. Volume 5, Issue 4, Supplement, Pages P138-P139 (July 2009).

6. Maccechini M, Greig NE, Rogers JT Targeting Alzheimer’s and other neurodegenerative diseases via a novel mechanism of action. Alzheimer’s and Dementia. 2010. Alzheimer’s disease congress. Versailles, France. Oral presentation.

7. Huang, X and Rogers, JT. Iron-regulatory Proteins and Neurodegenerative Diseases. Notes from University of Toronto. 2011, Toronto, Canada.

8. Jack T. Rogers, James Spoonamore, Catherine Cahill, Xudong, Huang. Novel Untranslated Region Directed Blockers of Amyloid Precursor Protein Translation; A role for therapy for Down syndrome and Alzheimer's disease. Drug Discovery and Therapy World Congress 2013, June 3-6, Boston, MA, USA.

9. Jack T. Rogers, Yanyan Liu, Qinjun Li, Nigel H. Greig, Debomoy K. Lahiri, Catherine M. Cahill,

Xudong Huang. A Novel 5’ Untranslated Region Translation Co-Blocker of the Amyloid Precursor Protein and Prion (PrP); Interface Therapy of Spongioformopathies and Alzheimer’s disease. Drug Discovery and Therapy World Congress 2014, June 16-19th, Boston, MA, USA.

10. Yanyan Liu, Vivek Venkataramani, Sarah Walecka, Catherine M. Cahill, Vinusha Tummala, Xudong Huang, Ashley I. Bush, Jack T. Rogers. International conference on brain disorders and Therapeutics. August 24- 25th, 2015 London UK.

11. Jack T. Rogers, Kevin J. Hodgetts, Kara Kimball Cover1,] Yanyan Liu, Kazuhide Hayakawa, Nigel H. Greig3, Debomoy K. Lahiri4, Catherine M. Cahill, Xudong Huang.

Drug Discovery and Therapy World Congress 2015, July 22nd -23rd, Boston, MA, USA. *Oral Presenter

Thesis. Rogers, JT. Oligonucleotide identification and molecular cloning the human alpha-1 antitrypsin and apolipoprotein CII genes. Ph.D. Thesis, University of London: St. Mary's Hospital; 1984. (available on interlibrary loan from the University of London, Imperial College London).

Narrative report of Research, Teaching, and Clinical Contributions.

Introduction: After receiving undergraduate training at Trinity College Dublin in Genetics, Dr. Rogers became a teaching assistant in the University of Pennsylvania where he received an M.Sc. degree in Genetics. He then completed my Ph.D. in Biochemistry (University of London). After completing a Ph.D. at Imperial College London, he became a Fellow at MIT and then was a Junior faculty member at Harvard University. He is currently the Program Director for the Neurochemistry Lab in the Psychiatric Neuroscience Division at the Massachusetts General Hospital.

Research: Jack Rogers’ laboratory now employs a dual track study of genetics of iron homeostasis coupled with translational regulation of the mRNAs for the amyloid precursor protein (APP) and the L- and subunits of the iron storage protein ferritin. The implication of perturbed iron balance as occurs in response to lead (Pb) and manganese (Mn) toxicity is relevant to diseases ranging from toxic environmental anemia to neurodegenerative Parkinson’s disease and Alzheimer's disease (AD). We published the cover issue of Journal of Biological Chemistry (Oct 2010) and in PloS-ONE (3013) and Biochemical Pharmacology (2014) and more recently contributed this activity to a 2015 J. Neuroscience paper (In Press) describing how the central iron homeostatic sensor Iron-regulatory Protein-1 sets the rate of APP translation.

The ‘Society for Biochemistry and Molecular Biology’ profiled the biographies of two of our key Neurochemistry Laboratory members, who were the co-first authors. http://www.jbc.org/content/285/41/e99973/suppl/DC1. A concurrent Cell paper (Sept. 2010) for the first time revealed that APP, which is critical during the pathogenesis of AD, is an iron export protein that prevents neurons accumulating excessive iron. Jack’s Neurochemistry La and MGH originally patented the concept that peptides from APP sequences can be employed as neuroprotective agents (US Patent 7034000, 2004) and he has currently expanded this to successfully placing for an international patent based on our amyloid precursor protein blockers.

Our laboratory’s central therapeutic strategy has been to work in collaboration with the Broad Institute and the Laboratory for Drug Discovery in Neurodegeneration (Cambridge, MA). We continue to focus on developing lead APP and alpha-synuclein translation inhibitors as therapeutic agents relevant to neurodegenerative diseases. In being recruited, our laboratory plans to follow up on our Cell and PLoS-ONE papers concerning our novel discovery of the underlying function of the Alzheimer’s amyloid precursor protein as a neuroprotective iron exporter that is critical component of the gene family that controls

intracellular iron homeostasis.

Dr. Jack Rogers was fortunate to receive several awards, including the Neuroscience Education Research Foundation Award from the University of California - San Diego. He is the recipient of the Zenith award (2010) from the Alzheimer’s Association and have received over 10 different NIH awards and numerous regional, national and international invited presentations and have two US patents (one pending). http://connects.catalyst.harvard.edu/profiles/profile/person/47607

Administration: This includes Dr. Rogers’s responsibilities to administer the day-to-day running of the Neurochemistry Laboratory and also serve on the Scientific Review Boards of the Institute for the Study of Aging and the American Federation for Aging Research. He is a reviewer for the Journal of Biological Chemistry, Nucleic Acids Research, the Journal of Neurochemistry and the top molecular biology journal, PLoS-ONE and as an NIH reviewer in the ‘Neuro-pharmacology’ Study Section (R01, R21, SBIR grants). He will continue to administer a full characterization of Neurochemistry’s top APP 5'UTR directed leads identified from a published high throughput (HTS) screen for novel APP translation blockers. We maintain an administrative collaboration with Dr. Sanghamitra Bandyopadhyay who high throughput screened a Harvard compound library that included natural products and novel chemical entities. The top lead APP 5’UTR blockers from this screen are now being developed as part of an international collaboration with the Institute of Toxicology, Lucknow, India. These novel patented agents are being developed for potential in vivo AD therapy in a current collaboration that Dr. Rogers maintains with Prof. Bruce Lamb at the Cleveland Clinic and Dr. Kevin Hodgetts at the Laboratory for Drug Discovery in Neurodegenerative Disease, BWH, Cambridge MA. In the last year Neurochemistry has undertaken new projects with Dr. Michael Schwarszchild to define how urate by offset both led (Pb) and manganese neurotoxicity the molecular level.

Teaching: Jack Rogers’s lab has directed research projects for undergraduates from Harvard College, Dartmouth College, Scripps College, the University of Pennsylvania, Texas Southwestern Medical School, Boston University, Northeastern University.

Dr. Rogers has taken responsibility every year to take charge of a tutorial group of incoming medical students in the course framework of the Molecular biology of disease at Longwood Ave (Dr. Randy King, MD. Ph.D., Director available as a referee attesting to this activity). This includes teaching a group for 90 minutes daily for six weeks every year. In September/October of 2015 Jack taught biochemistry and Pathology in the new Foundations course with Dr. Scott Lovich and Dr. Randy King (Course Directors).

Dr. Rogers has taught and taken charge of the Neuroscience Section for the International Molecular Biology Organization (IBRO) 2012-2015. (Dr. Hong Jiang, Host Institute is available as a referee attesting to this activity).

Dr. Rogers has considerable experience in teaching Lab courses, including with Mr. Sohan Mikkillineni, an MIT undergraduate student between 2010 and 2013. During this activity mentor and student discovered a physiologically significant RNA structure that was accepted for publication on a cover issue of JBC. They generated a 3D model of the RNA

stem loop that is folds into an “Iron-responsive Element ". This APP IRE was modeled by bioinformatics and can be viewed in the following link: - http://www.jbc.org/content/285/41.cover-expansion.

Dr. Rogers served as external supervisor to several Ph.D. students who finished their dissertations, namely Dr. Eric Hall, Penn State (2012), and Dr. Marlies Fischer (University College Dublin, 2012).

For the past years (2010- 2016).

Dr. Rogers has mentored Mr. Conan Huang to be accepted in Medical School at NYU (2014-2018). (Mr. Conan Huang is available as a referee attesting to this activity)Dr. Rogers has mentored the activity of a Boston University Undergraduate - Ms Susruthi Ranjala – who will be co-publishing their work on the ORF72C9 Gene that causes amyotrophic lateral sclerosis (2015).

Dr. Rogers has mentored the activity of a Texas Southwestern medical student Undergraduate – Ms. Monica Lu – who will be co-publishing their work on the ORF72C9 Gene that causes amyotrophic lateral sclerosis (2015).Mr. Brent Kisby, Undergraduate, Northeastern University, is currently pursuing a theoretical project with Jack Rogers to link neurogenesis to iron induction of amyloid precursor protein translation.Mr Mohammed Enes collaborated in the summer of 2015 to pursue a theoretical project with Jack Rogers to link neurogenesis to iron induction of amyloid precursor protein translation.